Using EAE to better understand principles of immune function and autoimmune pathology

Journal of Autoimmunity

Volumn 45, Issue , 2013, Pages 31-39

  Rangachari, Manu ^a,b   Kuchroo, Vijay K ^c  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Bat3; CD4+ T lymphocyte, myelin; Experimental autoimmune encephalomyelitis; Interleukin 17; Multiple sclerosis; Tim 3

Indexed keywords

MYELIN; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEIN TIM 3; PROTEOLIPID PROTEIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ALLERGIC ENCEPHALOMYELITIS; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM; HELPER CELL; IMMUNIZATION; IN VITRO STUDY; INFLAMMATION; INFLAMMATORY INFILTRATE; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TH17 CELL; TRANSGENIC MOUSE;

BAT3; CD4+ T LYMPHOCYTE, MYELIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; INTERLEUKIN-17; MULTIPLE SCLEROSIS; TIM-3;

ANIMALS; AUTOANTIGENS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MICE; MICE, TRANSGENIC; MULTIPLE SCLEROSIS; RECEPTORS, VIRUS; SIGNAL TRANSDUCTION; TH1 CELLS; TH17 CELLS;

EID: 84884281404     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.06.008     Document Type: Review

References (116)

1. Frohman E.M., Racke M.K., Raine C.S. Multiple sclerosis - the plaque and its pathogenesis. NEngl J Med 2006, 354:942-955.
2. Meuth S.G., Gobel K., Wiendl H. Immune therapy of multiple sclerosis - future strategies. Curr Pharm Des 2012, 18:4489-4497.
3. Cooper G.S., Bynum M.L., Somers E.C. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. JAutoimmun 2009, 33:197-207.
4. Richards T.L., Alvord E.C., He Y., Petersen K., Peterson J., Cosgrove S., et al. Experimental allergic encephalomyelitis in non-human primates: diffusion imaging of acute and chronic brain lesions. Mult Scler 1995, 1:109-117.
5. Aritake K., Koh C.S., Inoue A., Yabuuchi F., Kitagaki K., Ikoma Y., et al. Effects of human recombinant-interferon beta in experimental autoimmune encephalomyelitis in guinea pigs. Pharm Biol 2010, 48:1273-1279.
6. Pearce J.M. Historical descriptions of multiple sclerosis. Eur Neurol 2005, 54:49-53.
7. McDonald W.I. The dynamics of multiple sclerosis. The Charcot Lecture. JNeurol 1993, 240:28-36.
8. McDonald I. Multiple sclerosis in its European matrix. Mult Scler 2002, 8:181-191.
9. Wingerchuk D.M., Lucchinetti C.F., Noseworthy J.H. Multiple sclerosis: current pathophysiological concepts. Lab Invest 2001, 81:263-281.
10. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
11. Antel J., Antel S., Caramanos Z., Arnold D.L., Kuhlmann T. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?. Acta Neuropathol 2012, 123:627-638.
12. Tuohy V.K., Lu Z., Sobel R.A., Laursen R.A., Lees M.B. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. JImmunol 1989, 142:1523-1527.
13. Tompkins S.M., Padilla J., Dal Canto M.C., Ting J.P., Van Kaer L., Miller S.D. De novo central nervous system processing of myelin antigen is required for the initiation of experimental autoimmune encephalomyelitis. JImmunol 2002, 168:4173-4183.
14. Batoulis H., Recks M.S., Addicks K., Kuerten S. Experimental autoimmune encephalomyelitis - achievements and prospective advances. APMIS 2011, 119:819-830.
15. McRae B.L., Kennedy M.K., Tan L.J., Dal Canto M.C., Picha K.S., Miller S.D. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein. JNeuroimmunol 1992, 38:229-240.
16. Rangachari M., Zhu C., Sakuishi K., Xiao S., Karman J., Chen A., et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat Med 2012, 18:1394-1400.
17. Berard J.L., Wolak K., Fournier S., David S. Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice. Glia 2010, 58:434-445.
18. Domingues H.S., Mues M., Lassmann H., Wekerle H., Krishnamoorthy G. Functional and pathogenic differences of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. PLoS One 2010, 5:e15531.
19. Zamvil S., Nelson P., Trotter J., Mitchell D., Knobler R., Fritz R., et al. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 1985, 317:355-358.
20. Zamvil S.S., Mitchell D.J., Moore A.C., Kitamura K., Steinman L., Rothbard J.B. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature 1986, 324:258-260.
21. Kennedy M.K., Clatch R.J., Dal Canto M.C., Trotter J.L., Miller S.D. Monoclonal antibody-induced inhibition of relapsing EAE in SJL/J mice correlates with inhibition of neuroantigen-specific cell-mediated immune responses. JNeuroimmunol 1987, 16:345-364.
22. Whitham R.H., Wingett D., Wineman J., Mass M., Wegmann K., Vandenbark A., et al. Treatment of relapsing autoimmune encephalomyelitis with T cell receptor V beta-specific antibodies when proteolipid protein is the autoantigen. JNeurosci Res 1996, 45:104-116.
23. Kennedy M.K., Tan L.J., Dal Canto M.C., Tuohy V.K., Lu Z.J., Trotter J.L., et al. Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides. JImmunol 1990, 144:909-915.
24. McRae B.L., Vanderlugt C.L., Dal Canto M.C., Miller S.D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. JExp Med 1995, 182:75-85.
25. Whitham R.H., Bourdette D.N., Hashim G.A., Herndon R.M., Ilg R.C., Vandenbark A.A., et al. Lymphocytes from SJL/J mice immunized with spinal cord respond selectively to a peptide of proteolipid protein and transfer relapsing demyelinating experimental autoimmune encephalomyelitis. JImmunol 1991, 146:101-107.
26. McMahon E.J., Bailey S.L., Castenada C.V., Waldner H., Miller S.D. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005, 11:335-339.
27. Quintana F.J., Farez M.F., Izquierdo G., Lucas M., Cohen I.R., Weiner H.L. Antigen microarrays identify CNS-produced autoantibodies in RRMS. Neurology 2012, 78:532-539.
28. Miyagawa F., Gutermuth J., Zhang H., Katz S.I. The use of mouse models to better understand mechanisms of autoimmunity and tolerance. JAutoimmun 2010, 35:192-198.
29. Adlard K., Tsaknardis L., Beam A., Bebo B.F., Vandenbark A.A., Offner H. Immunoregulation of encephalitogenic MBP-NAc1-11-reactive T cells by CD4+ TCR-specific T cells involves IL-4, IL-10 and IFN-gamma. Autoimmunity 1999, 31:237-248.
30. Waldner H., Whitters M.J., Sobel R.A., Collins M., Kuchroo V.K. Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor. Proc Natl Acad Sci U S A 2000, 97:3412-3417.
31. Pollinger B., Krishnamoorthy G., Berer K., Lassmann H., Bosl M.R., Dunn R., et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. JExp Med 2009, 206:1303-1316.
32. Seong E., Saunders T.L., Stewart C.L., Burmeister M. To knockout in 129 or in C57BL/6: that is the question. Trends Genet 2004, 20:59-62.
33. Mendel I., Kerlero de Rosbo N., Ben-Nun A. Amyelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells. Eur J Immunol 1995, 25:1951-1959.
34. Suen W.E., Bergman C.M., Hjelmstrom P., Ruddle N.H. Acritical role for lymphotoxin in experimental allergic encephalomyelitis. JExp Med 1997, 186:1233-1240.
35. Korner H., Riminton D.S., Strickland D.H., Lemckert F.A., Pollard J.D., Sedgwick J.D. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. JExp Med 1997, 186:1585-1590.
36. Tran E.H., Prince E.N., Owens T. IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. JImmunol 2000, 164:2759-2768.
37. Malipiero U., Frei K., Spanaus K.S., Agresti C., Lassmann H., Hahne M., et al. Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas ligand-deficient lpr and gld mice. Eur J Immunol 1997, 27:3151-3160.
38. Eugster H.P., Frei K., Bachmann R., Bluethmann H., Lassmann H., Fontana A. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1. Eur J Immunol 1999, 29:626-632.
39. Du C., Sriram S. Increased severity of experimental allergic encephalomyelitis in lyn-/- mice in the absence of elevated proinflammatory cytokine response in the central nervous system. JImmunol 2002, 168:3105-3112.
40. Bettelli E., Sullivan B., Szabo S.J., Sobel R.A., Glimcher L.H., Kuchroo V.K. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. JExp Med 2004, 200:79-87.
41. Hjelmstrom P., Juedes A.E., Fjell J., Ruddle N.H. B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization. JImmunol 1998, 161:4480-4483.
42. Bullard D.C., Hu X., Adams J.E., Schoeb T.R., Barnum S.R. p150/95 (CD11c/CD18) expression is required for the development of experimental autoimmune encephalomyelitis. Am J Pathol 2007, 170:2001-2008.
43. Koh D.R., Fung-Leung W.P., Ho A., Gray D., Acha-Orbea H., Mak T.W. Less mortality but more relapses in experimental allergic encephalomyelitis in CD8-/- mice. Science 1992, 256:1210-1213.
44. Spahn T.W., Issazadah S., Salvin A.J., Weiner H.L. Decreased severity of myelin oligodendrocyte glycoprotein peptide 33-35-induced experimental autoimmune encephalomyelitis in mice with a disrupted TCR delta chain gene. Eur J Immunol 1999, 29:4060-4071.
45. Friese M.A., Fugger L. Pathogenic CD8(+) T cells in multiple sclerosis. Ann Neurol 2009, 66:132-141.
46. Crawford M.P., Yan S.X., Ortega S.B., Mehta R.S., Hewitt R.E., Price D.A., et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004, 103:4222-4231.
47. Ford M.L., Evavold B.D. Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis. Eur J Immunol 2005, 35:76-85.
48. Blanchard N., Shastri N. Coping with loss of perfection in the MHC class I peptide repertoire. Curr Opin Immunol 2008, 20:82-88.
49. Bettelli E., Pagany M., Weiner H.L., Linington C., Sobel R.A., Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. JExp Med 2003, 197:1073-1081.
50. Pau D., Al Zubidi N., Yalamanchili S., Plant G.T., Lee A.G. Optic neuritis. Eye (Lond) 2011, 25:833-842.
51. Litzenburger T., Fassler R., Bauer J., Lassmann H., Linington C., Wekerle H., et al. Blymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice. JExp Med 1998, 188:169-180.
52. Krishnamoorthy G., Lassmann H., Wekerle H., Holz A. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. JClin Invest 2006, 116:2385-2392.
53. Bettelli E., Baeten D., Jager A., Sobel R.A., Kuchroo V.K. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. JClin Invest 2006, 116:2393-2402.
54. Misu T., Fujihara K., Nakashima I., Miyazawa I., Okita N., Takase S., et al. Pure optic-spinal form of multiple sclerosis in Japan. Brain 2002, 125:2460-2468.
55. Jäger A., Dardalhon V., Sobel R.A., Bettelli E., Kuchroo V.K. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. JImmunol 2009, 183:7169-7177.
56. Encinas J.A., Wicker L.S., Peterson L.B., Mukasa A., Teuscher C., Sobel R., et al. QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing Il2. Nat Genet 1999, 21:158-160.
57. Degenhardt A., Ramagopalan S.V., Scalfari A., Ebers G.C. Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol 2009, 5:672-682.
58. Anderson A.C., Chandwaskar R., Lee D.H., Sullivan J.M., Solomon A., Rodriguez-Manzanet R., et al. Atransgenic model of central nervous system autoimmunity mediated by CD4+ and CD8+ T and B cells. JImmunol 2012, 188:2084-2092.
59. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. JImmunol 1986, 136:2348-2357.
60. Cherwinski H.M., Schumacher J.H., Brown K.D., Mosmann T.R. Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies. JExp Med 1987, 166:1229-1244.
61. de Waal Malefyt R., Figdor C.G., Huijbens R., Mohan-Peterson S., Bennett B., Culpepper J., et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. JImmunol 1993, 151:6370-6381.
62. Lucey D.R. Evolution of the type-1 (Th1)-type-2 (Th2) cytokine paradigm. Infect Dis Clin North Am 1999, 13:1-9.
63. Adorini L., Guery J.C., Trembleau S. Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases?. Autoimmunity 1996, 23:53-68.
64. Ferber I.A., Brocke S., Taylor-Edwards C., Ridgway W., Dinisco C., Steinman L., et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). JImmunol 1996, 156:5-7.
65. Krakowski M., Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996, 26:1641-1646.
66. Chu C.Q., Wittmer S., Dalton D.K. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. JExp Med 2000, 192:123-128.
67. Becher B., Durell B.G., Noelle R.J. Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12. JClin Invest 2002, 110:493-497.
68. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
69. Gran B., Zhang G.X., Yu S., Li J., Chen X.H., Ventura E.S., et al. IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. JImmunol 2002, 169:7104-7110.
70. Cua D.J., Sherlock J., Chen Y., Murphy C.A., Joyce B., Seymour B., et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003, 421:744-748.
71. Zhang G.X., Gran B., Yu S., Li J., Siglienti I., Chen X., et al. Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system. JImmunol 2003, 170:2153-2160.
72. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. Adistinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
73. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. JExp Med 2005, 201:233-240.
74. Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J., et al. Areceptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. JImmunol 2002, 168:5699-5708.
75. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
76. Mangan P.R., Harrington L.E., O'Quinn D.B., Helms W.S., Bullard D.C., Elson C.O., et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006, 441:231-234.
77. Veldhoen M., Hocking R.J., Flavell R.A., Stockinger B. Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease. Nat Immunol 2006, 7:1151-1156.
78. Nurieva R., Yang X.O., Martinez G., Zhang Y., Panopoulos A.D., Ma L., et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 2007, 448:480-483.
79. Korn T., Bettelli E., Gao W., Awasthi A., Jager A., Strom T.B., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
80. Bettelli E., Korn T., Kuchroo V.K. Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 2007, 19:652-657.
81. Fitch E., Harper E., Skorcheva I., Kurtz S.E., Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007, 9:461-467.
82. Scheinecker C., Smolen J.S. Rheumatoid arthritis in 2010: from the gut to the joint. Nat Rev Rheumatol 2011, 7:73-75.
83. Shao S., He F., Yang Y., Yuan G., Zhang M., Yu X. Th17 cells in type 1 diabetes. Cell Immunol 2012, 280:16-21.
84. Fletcher J.M., Lalor S.J., Sweeney C.M., Tubridy N., Mills K.H. Tcells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 2010, 162:1-11.
85. Maddur M.S., Miossec P., Kaveri S.V., Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 2012, 181:8-18.
86. Yeilding N., Szapary P., Brodmerkel C., Benson J., Plotnick M., Zhou H., et al. Development of the IL-12/23 antagonist ustekinumab in psoriasis: past,present, and future perspectives-an update. Ann N Y Acad Sci 2012, 1263:1-12.
87. Rich P., Sigurgeirsson B., Thaci D., Ortonne J.P., Paul C., Schopf R.E., et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013, 168:402-411.
88. Miossec P., Kolls J.K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012, 11:763-776.
89. Yosef N., Shalek A.K., Gaublomme J.T., Jin H., Lee Y., Awasthi A., et al. Dynamic regulatory network controlling TH17 cell differentiation. Nature 2013, 496:461-468.
90. Wu C., Yosef N., Thalhamer T., Zhu C., Xiao S., Kishi Y., et al. Induction of pathogenic T17 cells by inducible salt-sensing kinase SGK1. Nature 2013, 496:513-517.
91. Lang F., Bohmer C., Palmada M., Seebohm G., Strutz-Seebohm N., Vallon V. (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms. Physiol Rev 2006, 86:1151-1178.
92. Kleinewietfeld M., Manzel A., Titze J., Kvakan H., Yosef N., Linker R.A., et al. Sodium chloride drives autoimmune disease by the induction of pathogenic T17 cells. Nature 2013, 496:518-522.
93. Pentcheva-Hoang T., Corse E., Allison J.P. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 2009, 229:67-87.
94. McCoy K.D., Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol 1999, 77:1-10.
95. Karandikar N.J., Vanderlugt C.L., Walunas T.L., Miller S.D., Bluestone J.A. CTLA-4: a negative regulator of autoimmune disease. JExp Med 1996, 184:783-788.
96. Hurwitz A.A., Sullivan T.J., Krummel M.F., Sobel R.A., Allison J.P. Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis. JNeuroimmunol 1997, 73:57-62.
97. Perrin P.J., Maldonado J.H., Davis T.A., June C.H., Racke M.K. CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. JImmunol 1996, 157:1333-1336.
98. Hurwitz A.A., Sullivan T.J., Sobel R.A., Allison J.P. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proc Natl Acad Sci U S A 2002, 99:3013-3017.
99. Francisco L.M., Sage P.T., Sharpe A.H. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010, 236:219-242.
100. Salama A.D., Chitnis T., Imitola J., Ansari M.J., Akiba H., Tushima F., et al. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. JExp Med 2003, 198:71-78.
101. Zhu B., Guleria I., Khosroshahi A., Chitnis T., Imitola J., Azuma M., et al. Differential role of programmed death-ligand 1 and programmed death-ligand 2 in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. JImmunol 2006, 176:3480-3489.
102. Carter L.L., Leach M.W., Azoitei M.L., Cui J., Pelker J.W., Jussif J., et al. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. JNeuroimmunol 2007, 182:124-134.
103. Monney L., Sabatos C.A., Gaglia J.L., Ryu A., Waldner H., Chernova T., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415:536-541.
104. Sabatos C.A., Chakravarti S., Cha E., Schubart A., Sanchez-Fueyo A., Zheng X.X., et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol 2003, 4:1102-1110.
105. Sanchez-Fueyo A., Tian J., Picarella D., Domenig C., Zheng X.X., Sabatos C.A., et al. Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance. Nat Immunol 2003, 4:1093-1101.
106. Zhu C., Anderson A.C., Schubart A., Xiong H., Imitola J., Khoury S.J., et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005, 6:1245-1252.
107. Koguchi K., Anderson D.E., Yang L., O'Connor K.C., Kuchroo V.K., Hafler D.A. Dysregulated T cell expression of TIM3 in multiple sclerosis. JExp Med 2006, 203:1413-1418.
108. Yang L., Anderson D.E., Kuchroo J., Hafler D.A. Lack of TIM-3 immunoregulation in multiple sclerosis. JImmunol 2008, 180:4409-4414.
109. Jones R.B., Ndhlovu L.C., Barbour J.D., Sheth P.M., Jha A.R., Long B.R., et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. JExp Med 2008, 205:2763-2779.
110. Golden-Mason L., Palmer B.E., Kassam N., Townshend-Bulson L., Livingston S., McMahon B.J., et al. Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. JVirol 2009, 83:9122-9130.
111. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. JExp Med 2010, 207:2187-2194.
112. Zhou Q., Munger M.E., Veenstra R.G., Weigel B.J., Hirashima M., Munn D.H., et al. Co-expression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011.
113. Wherry E.J. Tcell exhaustion. Nat Immunol 2011, 12:492-499.
114. Gershwin M.E., Shoenfeld Y. Chella David: a lifetime contribution in translational immunology. JAutoimmun 2011, 37:59-62.
115. Jamin C., Renaudineau Y., Pers J.O. Pierre Youinou: when intuition and determination meet autoimmunity. JAutoimmun 2012, 39:117-120.
116. Tzioufas A.G., Kapsogeorgou E.K., Moutsopoulos H.M. Pathogenesis of Sjogren's syndrome: what we know and what we should learn. JAutoimmun 2012, 39:4-8.